{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:55:08Z","timestamp":1776398108663,"version":"3.51.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.7759\/cureus.107195","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:19:56Z","timestamp":1776395996000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.7759","author":[{"given":"Henry O","family":"Aiwuyo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irikefe  P","family":"Obiebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osagioduwa Mike","family":"Atoe-Imagbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uyilawa","family":"Okhuaihesuyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O","family":"Osarenkhoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony  G","family":"Kweki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher  O","family":"Iruolagbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa O","family":"Oboirien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwasegun  M","family":"Akinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel C","family":"Okakpu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ogie Derick","family":"Aghimien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovie","family":"Okorare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal C","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Tchapmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study","volume":"129","author":"Chugh SS","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al.. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. 2014, 129:837-47. 10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82285","article-title":"Atrial fibrillation in geriatric patients: a cross-sectional analysis of risk factors and disease patterns","volume":"17","author":"Palaparthi EC","year":"2025","unstructured":"Palaparthi EC, Titty NA, Bhuyar BK, Gudimalla A, Nandyala PS, Vivekanandan V, Kandimalla R. Atrial fibrillation in geriatric patients: a cross-sectional analysis of risk factors and disease patterns. Cureus. 2025, 17:e82285. 10.7759\/cureus.82285","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani SS","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al.. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020, 141:e139-596. 10.1161\/CIR.0000000000000757","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2021.04.027","article-title":"Structural cardiac remodeling in atrial\u00a0fibrillation","volume":"14","author":"Beyer C","year":"2021","unstructured":"Beyer C, Tokarska L, St\u00fchlinger M, et al.. Structural cardiac remodeling in atrial\u00a0fibrillation. JACC Cardiovasc Imaging. 2021, 14:2199-208. 10.1016\/j.jcmg.2021.04.027","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv375","article-title":"Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications","volume":"37","author":"Lau DH","year":"2016","unstructured":"Lau DH, Schotten U, Mahajan R, et al.. Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications. Eur Heart J. 2016, 37:1573-81. 10.1093\/eurheartj\/ehv375","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman RR","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017, 377:1228-39. 10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez AF","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al.. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.  Lancet. 2018, 392:1519-29. 10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein HC","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al.. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021, 385:896-907. 10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw045","article-title":"Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions","volume":"38","author":"Wong CX","year":"2017","unstructured":"Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017, 38:1294-302. 10.1093\/eurheartj\/ehw045","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.058","article-title":"Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity","volume":"66","author":"Mahajan R","year":"2015","unstructured":"Mahajan R, Lau DH, Brooks AG, et al.. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015, 66:1-11. 10.1016\/j.jacc.2015.04.058","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)","volume":"65","author":"Pathak RK","year":"2015","unstructured":"Pathak RK, Middeldorp ME, Meredith M, et al.. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015, 65:2159-69. 10.1016\/j.jacc.2015.03.002","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156463","article-title":"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials","volume":"175","author":"Karakasis P","year":"2026","unstructured":"Karakasis P, Vlachos K, Antoniadis AP, Siontis KC, Patoulias D, Fragakis N, Mantzoros CS. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026, 175:156463. 10.1016\/j.metabol.2025.156463","journal-title":"Metabolism"},{"key":"ref17","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2022","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, 2022."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.31083\/RCM45204","article-title":"The beneficial effects of glucagon-like peptide-1 agonists on blood pressure: a comprehensive review","volume":"26","author":"Gala D","year":"2025","unstructured":"Gala D, Botros F, Makaryus AN. The beneficial effects of glucagon-like peptide-1 agonists on blood pressure: a comprehensive review. Rev Cardiovasc Med. 2025, 26:45204. 10.31083\/RCM45204","journal-title":"Rev Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma X","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, et al.. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021, 17:2050-68. 10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01715-w","article-title":"Real-world comparisons between glucagon-like peptide-1 receptor agonists and other glucose-lowering agents in type 2 diabetes: retrospective analyses of cardiovascular and economic outcomes in England","volume":"16","author":"Connolly D","year":"2025","unstructured":"Connolly D, Collins E, Ren H, Wan Yau Ming S, Davidson J, Bain S. Real-world comparisons between glucagon-like peptide-1 receptor agonists and other glucose-lowering agents in type 2 diabetes: retrospective analyses of cardiovascular and economic outcomes in England. Diabetes Ther. 2025, 16:955-75. 10.1007\/s13300-025-01715-w","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473133-association-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-atrial-fibrillation-adverse-events-a-systematic-review-and-meta-analysis-of-randomized-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:19:59Z","timestamp":1776395999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473133-association-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-atrial-fibrillation-adverse-events-a-systematic-review-and-meta-analysis-of-randomized-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.107195","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}